Full Text View
Tabular View
No Study Results Posted
Related Studies
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization
This study has been completed.
Study NCT00297661   Information provided by University of Bern

First Received on February 22, 2006.   Last Updated on October 19, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Coronary Heart Disease
Additional conditions recognized in this trial
Coronary Artery Disease
Coronary Disease
Heart Diseases
Myocardial Ischemia
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Vascular Diseases
Interventions listed in this trial
Sirolimus-eluting stent
Paclitaxel-eluting stent
Additional drug interventions recognized in this trial
Everolimus
Paclitaxel
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
University of Bern
University of Zurich


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services